U

UroGen Pharma, Inc

Develops RTGel-based drug delivery for uro-oncology

Director Nonclinical Development

Translational Research & Bench BiologyConfirmed live in the last 24 hours
Full-timePhiladelphia, PA, USANo salary listed

About the Job

Requirements

  • A Ph.D. in pharmacology, pathology, or another related discipline, or a PharmD or DVM with appropriate experience.
  • At least five years of relevant biotechnology or pharmaceutical industry experience, with demonstrated expertise in nonclinical pharmacology, pharmacokinetics, and toxicology.
  • Demonstrated expertise designing and overseeing outsourced in vivo pharmacology, pharmacokinetic, efficacy, and safety studies, including GLP toxicology for drug development programs.
  • Demonstrated expertise drafting nonclinical sections of IND submissions.
  • A strong understanding of the nonclinical evidence and regulatory requirements needed to advance biologic programs into the clinic.
  • Ability to interpret multidisciplinary data, manage competing priorities, and communicate clear recommendations to technical and executive audiences.
  • Strong scientific judgment, project leadership, collaboration, and written and verbal communication skills.
  • Ability and willingness to work regularly in person in Philadelphia and travel according to need; remote work is supported.

Responsibilities

  • Lead the strategy, design, and execution of in vivo feasibility, safety, toxicology, pharmacokinetic, biodistribution, and efficacy studies.
  • Translate program objectives into fit-for-purpose study plans, including model and species selection, endpoints, protocols, timelines, and decision criteria.
  • Select and manage CROs, consultants, and academic partners; oversee proposals, budgets, study conduct, data quality, troubleshooting, and final reports.
  • Lead GLP toxicology studies and associated toxicokinetic, bioanalytical, and pathology activities in compliance with applicable regulatory standards.
  • Critically review and integrate nonclinical data, assess program risks, and present evidence-based recommendations to project teams and leadership.
  • Draft and review nonclinical sections of IND submissions, Investigator's Brochures, regulatory responses, and other development documents.
  • Work closely with Pharmaceutical R&D, Clinical Development, Medical Devices, Quality, and Regulatory Affairs to align nonclinical plans with clinical and regulatory objectives.
  • Evaluate new research areas, treatment modalities, indications, and external technologies.
  • Support scientific due diligence for licensing, partnering, and other business development opportunities.

Desired Qualifications

  • Expertise in local drug delivery, oncolytic viruses, virology, immunology, or bioanalytical method development.

About the Company

UroGen Pharma, Inc

Develops RTGel-based drug delivery for uro-oncology

UroGen Pharma develops RTGel-based drug-delivery therapies for urothelial and specialty cancers, commercializing products like Jelmyto and ZUSDURI and advancing a pipeline that includes UGN-102, UGN-103, UGN-104, and UGN-301. Its RTGel platform is liquid at cool temperatures and gels at body temperature, allowing chemotherapy to stay at the treatment site longer for local, sustained exposure. The company differentiates itself by delivering established chemotherapy directly to the disease site to reduce systemic exposure and by building a multi-product portfolio focused on urothelial cancers. Its goal is to improve local treatment outcomes and grow a diversified, globally commercial portfolio through ongoing clinical development and partnerships.

Company size
201-500
Company stage
IPO
Headquarters
Princeton, NJ
Founded
2004

Recently Posted Jobs

Explore more opportunities at UroGen Pharma, Inc

See more jobs